Literature DB >> 19779034

MicroRNAs and prostate cancer.

Valeria Coppola1, Ruggero De Maria, Désirée Bonci.   

Abstract

Despite much progress in prostate cancer management, new diagnostic, prognostic and therapeutic tools are needed to predict disease severity, choose among the available treatments and establish more effective therapies for advanced prostate cancer. In the last few years, compelling evidence has documented the role of microRNAs as new broad-spectrum oncogenes or tumour suppressor genes, thus their use as diagnostic, prognostic and therapeutic biomolecules is envisaged. This review extensively and critically summarizes the current knowledge about microRNA deregulation in prostate cancer disease, underlining present limits and future perspectives.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 19779034     DOI： 10.1677/ERC-09-0172

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN： 1351-0088            Impact factor:   5.678


  70 in total

1.  MicroRNA detection in prostate tumors by quantitative real-time PCR (qPCR).

Authors:  Aida Gordanpour; Robert K Nam; Linda Sugar; Stephanie Bacopulos; Arun Seth
Journal:  J Vis Exp       Date:  2012-05-16       Impact factor: 1.355

Review 2.  Missing link between microRNA and prostate cancer.

Authors:  Balraj Singh Gill; Jimi Marin Alex; Sanjeev Kumar
Journal:  Tumour Biol       Date:  2016-01-28

3.  miR-888 is an expressed prostatic secretions-derived microRNA that promotes prostate cell growth and migration.

Authors:  Holly Lewis; Raymond Lance; Dean Troyer; Hind Beydoun; Melissa Hadley; Joseph Orians; Tiffany Benzine; Kenya Madric; O John Semmes; Richard Drake; Aurora Esquela-Kerscher
Journal:  Cell Cycle       Date:  2013-11-07       Impact factor: 4.534

Review 4.  The roles of microRNAs in the progression of castration-resistant prostate cancer.

Authors:  Satoko Kojima; Yusuke Goto; Yukio Naya
Journal:  J Hum Genet       Date:  2016-06-09       Impact factor: 3.172

5.  MAPK and JAK/STAT pathways targeted by miR-23a and miR-23b in prostate cancer: computational and in vitro approaches.

Authors:  Seyed Hamid Aghaee-Bakhtiari; Ehsan Arefian; Mahmood Naderi; Farshid Noorbakhsh; Vahideh Nodouzi; Mojgan Asgari; Pezhman Fard-Esfahani; Reza Mahdian; Masoud Soleimani
Journal:  Tumour Biol       Date:  2015-01-22

6.  Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression.

Authors:  Pei-Chun Lin; Ya-Lin Chiu; Samprit Banerjee; Kyung Park; Juan Miguel Mosquera; Eugenia Giannopoulou; Pedro Alves; Ashutosh K Tewari; Mark B Gerstein; Himisha Beltran; Ari M Melnick; Olivier Elemento; Francesca Demichelis; Mark A Rubin
Journal:  Cancer Res       Date:  2012-12-11       Impact factor: 12.701

7.  Post-transcriptional processing of genetic information and its relation to cancer.

Authors:  Lr McNally; U Manne; W E Grizzle
Journal:  Biotech Histochem       Date:  2013-01-04       Impact factor: 1.718

Review 8.  Nanoways to overcome docetaxel resistance in prostate cancer.

Authors:  Aditya Ganju; Murali M Yallapu; Sheema Khan; Stephen W Behrman; Subhash C Chauhan; Meena Jaggi
Journal:  Drug Resist Updat       Date:  2014-04-05       Impact factor: 18.500

9.  Blood-based microRNAs as diagnostic biomarkers to discriminate localized prostate cancer from benign prostatic hyperplasia and allow cancer-risk stratification.

Authors:  Ghada Al-Kafaji; Harun Muayad Said; Mahmood Abduljalil Alam; Ziad Tarraq Al Naieb
Journal:  Oncol Lett       Date:  2018-05-22       Impact factor: 2.967

10.  Regulators of gene expression as biomarkers for prostate cancer.

Authors:  Stacey S Willard; Shahriar Koochekpour
Journal:  Am J Cancer Res       Date:  2012-11-20       Impact factor: 6.166
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.